The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughout the world. The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not-and how-to treat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs). The aim of this observational study was to evaluate whether DAA antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option. Twenty (13 males and 7 females) HCV genotype 1b-positive subjects, undergoing chemotherapy for DLBCL, were enrolled between June 2015 and December 2015. After informed consent, all patients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL. Complete hematological (Revised European-American Lymphoma classification, Ann Arbor, and International Prognostic Index [IPI] scores) and hepatological (viral markers, liver stiffness, and biochemical parameters) evaluations were made. A historical retrospective cohort of 101 DLBCL/HCV-positive patients not undergoing AVT was enrolled for comparison. DAA-treated and untreated patients were similar for sex distribution, IPI score, and NHL stage, and differed for age (older in treated), chemotherapy and use of AVT. Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-week of follow-up. No statistical difference was found in OS after 52 weeks (P 5 0.122), whereas a statistically significant higher DFS was achieved in treated patients (P 5 0.036). At the multivariate analysis, only IPI score and AVT were independently correlated with a better DFS. No differences in adverse events were reported. Conclusion: DAA treatment in concomitance with chemotherapy was shown to be safe and effective in influencing remission of aggressive lymphomas in HCV patients. (HEPATOLOGY 2018;67:48-55).
I n the last 20 years, the treatment of (HCV)-related chronic hepatitis saw the development of multiple different therapeutic regimens, with an increase of their efficacy overtime. The most recent treatments with direct antiviral agents (DAAs) are the extraordinary peak of this scientific progress, with 80%-100% of patients experiencing sustained virological response (SVR) to the therapy, depending on the stage of the disease and the virus genotype.
The clinical expression of chronic HCV infection does not only include liver disease. Several scientific observations suggest that chronic HCV infection might also be responsible for extrahepatic disease. (1, 2) The association of non-Hodgkin's lymphomas (NHLs) and HCV is common throughout world, with few exceptions. (3) (4) (5) (6) (7) (8) The differences in HCV prevalence in NHL patients may be attributable to either a different genetic background (9) or a possible bias attributed to studies conducted in geographical areas highly endemic for HCV. (10) (11) (12) However, the direct and/or indirect role of HCV in the pathogenesis of NHL is still a matter of debate. (6) Nevertheless, some researchers documented a major risk of NHL in HCV-positive patients, (13, 14) confirmed also by data showing a different incidence rate for NHL in HCVpositive patients, depending on the achievement of an SVR though antiviral therapy (AVT). (15, 16) Currently, around 90% of patients with a diagnosis of chronic hepatitis and/or compensated cirrhosis clear the virus (SVR) with DAA treatment. (17) The management of HCV-positive NHL patients is based on the treatment of NHL with standard chemotherapy. Some researchers documented the possibility of treating primary splenic lymphomas and in general low-grade (marginal zone) lymphomas in HCV patients with pegylated interferon (PEG-IFN)-based antiviral regimens as a first-line therapy. (18, 19) According to that, the PEG-IFN plus ribavirin regimen was shown to lead remission in HCVrelated low-grade NHL, in which the HCV-RNA negativity was achieved. (19, 20) Moreover, preliminary data of interferon (IFN)-free DAA therapy in indolent HCVpositive NHL seem to confirm their activity in inducing lymphoma regression. (21) (22) (23) Nonetheless, chemotherapy remains the only possible choice for more-severe B-cell non-Hodgkin lymphomas (B-NHLs). Based on this evidence, all national and international guidelines on the prescription of the new DAAs in HCV-positive subjects included in the population to be treated patients with hematological disorders, such as cryoglobulinemic syndrome and B-NHLs. (17) In addition, the Italian Drug Agency (AIFA) included the aforementioned hematological disorders in the priority criteria for HCV AVT. (24) Finally, recent reports have highlighted how DAAs seem to be safe when used in conjunction with selected chemotherapies. (25) (26) (27) The question therefore arises whether or not-and how-to treat HCV-positive patients suffering from more-aggressive B-NHL.
The aim of this consecutive prospective study was to evaluate whether the AVT with DAAs of B-NHL/ HCV-infected patients in concomitance with chemotherapy is a safe therapeutic option and whether it might positively affect the outcome of NHL.
Patients and Methods

STUDY COHORT
The study cohort included 20 consecutive HCVpositive genotype 1b-infected patients affected with diffuse large B-cell lymphoma (DLBCL) NHL (13 males and 7 females), referred to three different tertiary centers for hepatology of South Italy, for a clinical and therapeutic evaluation with the new DAAs. The patients studied were under simultaneous observation for the management of the NHL disease at three different hematological tertiary centers of South Italy. The enrollment period started at the beginning of June 2015 and ended on December 31, 2015. In concomitance with an antineoplastic treatment, all patients were treated orally with the sofosbuvir-ledipasvir combination (Harvoni, 1 pill once a day for 12 weeks). SVR was defined as the disappearance of serum HCV RNA 12 weeks after the end of therapy ("DAAtreated patients"). A historical cohort of 101 HCVpositive patients with an aggressive DLBCL NHL-
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From the 1 who did not undergo any AVT and who had similar clinical characteristics and had undergone similar antineoplastic therapies-were retrospectively enrolled at the same three hematological tertiary centers over the last 10 years, for statistical comparisons. Patients and historical controls ("untreated patients") were observed for 1 year after the complete remission from NHL after the first chemotherapy.
Inclusion criteria were: diagnosis of aggressive DLBCL NHL and indication for antineoplastic treatment (patients underwent the best treatment of choice, in accord with the hematological guidelines in force at the moment of the diagnosis of neoplasia), (28) (29) (30) (31) (32) together with genotype 1b HCV active infection at the onset of the neoplastic disease. Exclusion criteria were: indolent lymphoma; current and/or previous hepatitis B virus (HBV) infection; presence of clinical decompensated cirrhosis.
All patients gave their written informed consent to the data collection and the conduction of the study. The present study was conducted in compliance with the 1975 Declaration of Helsinki and was approved by our local Ethics Committee.
HEMATOLOGICAL EVALUATION
The diagnosis of NHL was biopsy proven and classified according to the Revised European-American Lymphoma (REAL) criteria and secondarily separated into aggressive and indolent lymphomas, according to a clinical prognostic classification used elsewhere. (33, 34) The NHL stage was defined by the Ann Arbor classification according to physical examination, total body computer tomography scan, and bone marrow biopsy. Age, Ann Arbor stage, lactate dehydrogenase levels, performance status, and presence/absence and number of extra lymph node extensions of the neoplastic disease were all taken into account to calculate the International Prognostic Index (IPI) score. (35) Complete remission was defined as the absence of disease for at least 1 month after the end of chemotherapy.
HEPATOLOGICAL EVALUATION
All patients included in the study were screened for HCV and HBV infection, which in our geographic area are highly prevalent chronic infections. HBV infection was based on positivity for HBsAg (antibodies by enzyme-linked immunosorbent assay [ELISA] Ortho Diagnostic Systems Inc., Raritan, NJ). HCV infection on positivity for both serum HCV-Ab (with commercial ELISA III; Abbot Laboratories, Chicago, IL), HCV-RNA, and HCV genotypes by PCR (Cobas TaqMan v2.0; Roche Molecular Systems Inc., Branchburg, NJ). All the subjects in the antiviral-treated group were tested for liver fibrosis (LF), with a transient elastography (TE) measurement with a Echosense Fibroscan device model 502 (EchoSens, Paris, France), before the start of treatment.
FOLLOW-UP, ENDPOINTS, AND STATISTICAL ANALYSIS
During antiviral treatment, all the patients were strictly followed up, with weekly evaluations of their liver function and for the eventual appearance of adverse events (AEs) or drug-to-drug interactions. After that, in accord with the goal of the study, followup data were prospectively (for DAA-treated patients) and retrospectively (for historical cohort patients) collected for up to 52 weeks (1 year), in order to define the disease-free survival (DFS) and overall survival (OS).
The statistical analysis was performed by using IBM-SPSS (Statistical Package for Social Science; v.20 for MacIntosh; IBM Corp, Armonk, NY). DAA-treated and "historically" untreated patient groups were compared by using a chi-square test for dichotomous variables, and a Student t testor MannWhitney U test for continuous variables, and matched by executing a propensity score evaluation for homogeneity. The cumulative risk for relapse of NHL (DFS) or death (OS) during the follow-up was assessed through Kaplan-Meier curves, and the comparison between NHL patients treated or not with AVT was performed through the log-rank test. The adjusted influence of AVT on the risk of developing an NHL relapse was analyzed with Cox proportional hazards models, by introducing covariates that were related to these events in a univariate analysis (P 0.1). The contribution of each significant variable to the risk of reaching the endpoint was estimated by the relative hazard, with its 95% confidence intervals (CIs). Significance was established at P < 0.05.
Results
Demographical and histological characteristics of our study population are presented in Table 1 . DAAtreated patients did not differ from HCV historical cohort subjects in terms of sex distribution, IPI scores prevalence, and NHL stage. The only statistically significant differences were age (older in DAA-treated patients), AVT (which was not used in the historical cohort), and types of antineoplastic therapies that showed a higher prevalence of rituximab (RTX)-containing protocols in DAA-treated patients compared to the historical controls, attributed to the fact that this cohort includes patients enrolled starting 10 years ago (a time in which RTX-containing protocols were less commonly used). LF fibrosis was assessed before the start of treatment with antivirals in the patients under study, by performing a TE (see Table 1 ): 16 patients had a mild LF (7.5 kilopascals [kPa]), and 4 had a liver stiffness that was compatible with moderate-toadvanced fibrosis (>7.5 kPa); the mean liver stiffness measurement was 12.7 (67.14). Chemotherapy response rates are also reported in Table 1 : A significantly higher rate of complete response after the firstline chemotherapy course was observed in DAAtreated patients in respect to the HCV historical cohort (P 5 0.006).
The rates of response to the AVT course for HCV infection with sofosbuvir plus ledipasvir are reported in Fig. 1 . Of the 20 patients who were treated with DAAs, only 1 patient discontinued therapy ("dropout") at week 9, attributed to NHL-related symptoms (grade 3 febrile neutropenia), but remained HCV-RNA negative thereafter and achieved an SVR. The other 19 patients achieved an end-term response and an SVR at week 12 after treatment. OS of DAA-treated and untreated patients is reported in Fig. 2 . At week 22 of the follow-up, 1 patient died from NHL-related complications in the DAA-treated patient arm, compared to 21 patients in the nontreated arm. The actuarial probability of being alive at 12, 24, and 48 weeks was 100%, 95%, and 95% in DAA-treated patients and 92.1%, 83.0%, and 80.5% in nontreated patients, respectively, without any statistically significant difference (P 5 0.122). On the contrary, DFS was significantly improved in DAAtreated patients compared to untreated patients (P 5 0.036). There was only 1 NHL relapse in the DAAtreated group (the same patient who died thereafter), compared to the 25 relapses that occurred among the untreated patients during the follow-up. The actuarial probability of being free from the relapse of neoplastic disease at 12, 24, and 48 weeks was 100%, 95%, and 95% in DAA-treated patients and 85.6%, 77.5%, and 67.1% in nontreated patients, respectively.
Then, we evaluated whether any clinical characteristic may have influenced DFS in DAA-treated and untreated patients. For this reason, we made a multivariate analysis, by performing a Cox proportional hazard model, through the introduction of the variables that, at the univariate, reached at least a P 0.1 (age, IPI score, AVT, and type of chemotherapy). The results are reported in Table 3 Finally, the AEs from the AVT and chemotherapy courses are reported in Table 3 . No statistically significant differences are reported in terms of serious adverse events (SAEs) and non-SAEs between the study populations.
Discussion
HCV has been identified as a causative agent of severe diseases, separate from chronic hepatitis and described in literature as "extrahepatic manifestations DAA treatment and NHL histology are independent variables for a different DFS.
of HCV." (2) In particular, HCV might be considered the etiological agent of either cryoglobulinemic syndrome or low-grade B-NHL. (2) In support to this are reports that, separately, outline the possibility of the HCV-core protein interfering with the proliferating pathway sustained by the activation of phosphoinositide 3-kinase, (36) the importance of a long-term duration of infection to generate an experimentally induced lymphomagenesis by HCV, (37) and the role of the genetic factors (i.e., interleukin-10 polymorphism) in influencing the natural course of HCV infection. (9) In the last decade, solid evidence from the literature showed the benefits of first-line AVT with IFN in low-grade B-NHLs. (2) Patients who achieved HCV eradication with AVT showed also a long-lasting remission of lymphoma. (2, (18) (19) (20) (21) (22) As for DLBCLNHLs, aggressive in nature, other researchers with anecdotal case reports (21, 23) -and ourselves in a previous retrospective study-analyzed the clinical outcome of NHL in HCV-infected patients who underwent AVT, versus those who did not, and found that in the former group of subjects, DFS was significantly better than in those who did not receive any AVT. (38) In particular, in this study the IFN-based AVT started after completion of antineoplastic treatment and the ascertainment of remission of NHL; for this reason, the beneficial effect of AVT was likely related to the eradication of HCV infection. In partial support of this hypothesis, Zignego et al. showed that the chromosomal aberration, t(14;18), responsible for the clonal proliferation in cryoglobulinemia (39) secondarily reverted after eradication of the virus through AVT, thus suggesting a direct proliferative effect of HCV on lymphocytes. (40) In the last 3 years, the advent of new AVT with DAA has unveiled a new era in the history of The bolded rows are the "summary" of AE and SAE that occurred in chemotherapies. HCV-related chronic hepatitis. The ease of the treatment schedule, the rate of SVR-reaching peaks of 100% in almost all HCV genotypes, with a very safe and well-tolerated profile of all the drugs currently in use-made the antiviral eradication protocol very easy to prescribe. (17) This, in our mind-also considering what is reported below in terms of efficacy of AVT on DFS and OS in B-NHLs-was a not-to-be-missed opportunity, especially for those neoplastic patients with a more aggressive form of lymphoma. A combined simultaneous therapeutic schedule was agreed upon between the hepatologists and hematologists, mainly considering possible pharmacological interference(s) between the selected DAA and the possible antineoplastic drugs, and none was found, either in terms of pharmacokinetic or in disease activity. This choice was also in agreement with recent reports in which DAA use in association with selected chemotherapies was found to be substantially safe. (25) (26) (27) In our study, all the patients but 1 did not experience any SAE, nor did they discontinue their treatment. Only 1 patient died in the course of therapy, and this was an event related not to the drugs in use, but to the severity of the hematological disease itself. Altogether, this supports the idea that the treatment schedule used appears to be safe and well tolerated. All the patients, except 1, reached the end of the AVT, and all experienced an SVR. We found that none of the 20 patients treated who showed a SVR to the AVT experienced any relapse of the underlying disease, whereas the historical control group had NHL relapse during the same period of follow-up. Moreover, with the new DAAs, the IFN-related antiproliferative properties of the "old" AVT shut down and the "pure" anti-HCV activities of the new agents answer the question of whether the HCV replication is directly correlated with B-cell monoclonal proliferation. Taken together, the data reported here endorse the concept that eradication of the infection positively affects the outcome of NHL and confirm once more a pathogenic role for HCV in NHL.
The role of anti-HCV therapy in the management of lymphoproliferative disorders is still a controversial issue. Whereas anti-HCV therapy was suggested as a first-line therapy in cryoglobulinemia, in HCVpositive primitive splenic and low-grade NHLs, chemotherapy is still the first-line treatment recommended by consensus panels of experts, particularly in aggressive lymphomas. (2, 41, 42) We believe that both the evidence from this study and, above all, the extraordinary higher rate of SVR currently achieved with the new DAAs should encourage the use of this combined approach, mostly because it is safe and well tolerated. The main limitations of this study are the short follow-up post-SVR, small number of patients enrolled, nonrandomized study design, and retrospective nature of the control arm; therefore, it does not seem appropriate to draw definitive conclusions regarding DFS and OS in such patients. Nevertheless, the optimal response, in terms of safety and SVR, endorses the use of this combined regimen in B-NHL patients.
In conclusion, our data confirm a pathogenic role for HCV in the development of NHL and suggest that AVT with DAA may represent a useful and safe approach for HCV-positive NHLs in combination with chemotherapeutic regimens in order to reinforce the remission of the neoplastic disease.
